ImmuPharma PLC announced that it has initiated a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform. P140 is ImmuPharma's technology platform for its portfolio in autoimmune diseases. This comprises the lead indication commencing a Phase 3 clinical study in systemic lupus erythematosus ("SLE") and the second indication, in preparation for a Phase 2/3 adaptive clinical study in chronic idiopathic demyelinating polyneuropathy ("CIDP").

New insights into the P140 technology lends itself to expanding the current patent portfolio. This new patent initiative will strengthen the commercial value of P140 and add to the positive engagement company already experiencing in discussions with a broad range of potential commercial partners on SLE and CIDP. New patents will not only significantly enhance the patent protection for P140 in SLE and CIDP but will also support patient studies in other auto-immune/inflammatory diseases and release further value from the P140 technology platform.